1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Nang Kuang Pharmaceutical Co., Ltd.

Nang Kuang Pharmaceutical Co., Ltd.

TTWSE:1752
31.10
TWD
-0.15
(-0.48%)
2.01EPS
16.51P/E
3.38BMarket Cap
Nov 06Next Earn
Nang Kuang Pharmaceutical Co., Ltd.
TWSE:1752
(Taiwan Stock Exchange)

Recent

price

31.10

P/E

ratio

16.51

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
10.36
12.91
14.39
11.85
14.33
16.6
15.44
14.89
15.24
17.59
17.38
17.63
19.21
21.29
21.78
21.41
20.84
Revenue per Share
-0.17
0.1
1.22
-0.09
0.76
2.17
2.25
1.84
1
2.17
1.82
1.94
3.49
1.96
2.41
2.42
2.03
Basic EPS, GAAP
-2.76
-2.67
-3.01
-1.23
1.35
0.54
1.75
1.17
2.07
3.11
0.59
3.93
2.72
0.41
-0.59
1.81
1.38
Free Cash Flow per Basic Share
0.2
- -
0.19
0.26
0.28
0.49
1.2
1.6
1.6
0.9
1.2
1.5
1.55
2
1
0.8
- -
Dividend per Share
11.17
11.06
12.46
15.99
16.17
20.97
21.02
21.22
20.52
21.66
21.83
22.18
23.87
23.54
23.98
24.6
23.84
Book Value per Share
11.15
11.05
12.45
15.96
16.09
20.87
20.91
21.14
20.45
21.62
21.8
22.13
23.84
23.49
23.94
24.55
23.75
Tangible Book Value per Share
63
63
66
85
89
92
100
101
101
100
101
101
101
101
101
101
101
Basic Weighted Avg Shares
653
813
952
1,013
1,277
1,520
1,550
1,504
1,539
1,762
1,755
1,780
1,940
2,150
2,200
2,162
2,109
Sales/Revenue/Turnover
-2.82
2.33
8.94
-0.04
7.18
13.88
14.83
10.71
8.3
14.07
12.83
14.41
16.69
15.75
13.98
13.67
12.39
Operating Margin (%)
85
99
103
121
153
164
172
178
196
193
185
180
176
182
183
183
181
Depreciation Expense
-11
6
81
-8
67
199
225
186
101
217
183
196
352
198
243
244
205
Net Income, GAAP
- -
43.07
14.11
237.11
18.54
12.2
16.55
14.63
14.02
13.31
17.98
16.46
14.28
7.15
19.72
16.21
16.13
Effective Tax Rate (%)
-1.62
0.76
8.5
-0.77
5.27
13.09
14.55
12.36
6.58
12.34
10.45
11.02
18.14
9.23
11.06
11.3
9.74
Profit Margin (%)
174
1
44
495
482
452
331
248
183
398
485
418
600
255
313
428
463
Working Capital
718
666
860
851
790
356
208
156
104
53
50
39
26
13
168
186
305
LT Debt
803
795
921
1,426
1,441
1,994
2,123
2,143
2,053
2,187
2,205
2,240
2,411
2,377
2,422
2,490
2,412
Total Equity
- -
0.59
3.44
0.03
3.03
7.01
6.75
4.69
3.98
8.25
6.83
7.89
9.68
8.23
8.22
7.94
7.12
Return on Invested Capital (%)
- -
0.79
4.48
-0.93
3.01
7.89
8.18
6.51
3.85
8.57
7.05
7.29
12.73
7.07
8.2
8.12
7.05
Return on Capital (%)
-1.31
0.77
9.43
-0.67
4.69
11.58
10.95
8.71
4.82
10.26
8.35
8.82
15.14
8.29
10.14
9.96
8.57
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
470
509
379
LT Borrowings
186
184
302
LT Finance Leases
- -
- -
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
101
101
101
Market Capitalization
3,767
3,615
3,383

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,493
1,514
1,605
Cash, Cash Equivalents & STI
351
331
385
Accounts Receivable, Net
253
265
273
Inventories
663
666
704
Total Current Liabilities
1,065
1,242
1,141
Payables & Accruals
- -
- -
- -
ST Debt
470
509
379
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.31%
2.51%
2.8%
Free Cash Flow
7.1%
-39.24%
-407.68%
Net Income, GAAP
11.52%
13.18%
0.41%
Sales/Revenue/Turnover
3.73%
4.37%
-1.71%
Total Cash Common Dividend
- -
-2.53%
-20%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
528
512
580
579
2,200
2025
579
542
524
517
2,162
2026
530
539
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.54
0.44
0.58
0.86
2.41
2025
0.71
0.51
0.46
0.73
2.42
2026
0.32
0.52
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
0.8
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Nang Kuang Pharmaceutical Co., Ltd. manufactures, processes, trades, imports, and exports pharmaceuticals and medical devices principally in Taiwan, China, Japan, the United States, and other international markets. Founded in 1963 and headquartered in Xinhua District, Tainan City, Taiwan, the company specializes in sterile injectables including ready-to-use injections, prefilled syringes, premixed IV infusions, powder injections, and non-PVC IV infusion bags; solid formulations such as hard capsules, tablets, film-coated tablets, granules, and creams; and therapeutic products covering cardiovascular, gastrointestinal, nervous system, musculo-skeletal, respiratory, alimentary and metabolism, blood and hematological agents, antineoplastic and immunomodulatory drugs, dermatologicals, genito-urinary and sex hormones, systemic hormones, antibacterials, cosmetics, eye drops, anti-aging and preventive medicines, chemotherapy and oncology products, as well as hospital solutions. It operates manufacturing facilities certified under PIC/S GMP by Taiwan's health authority and Japan's PMDA, with ISO 14001 and TIPS certifications, and holds export approvals to multiple countries. In recent developments, Nang Kuang launched new sleep-aid treatment Ramesson and benign prostatic hyperplasia treatment Finta to boost market share in quality-of-life medications, projecting continued revenue growth into 2025; the company maintains strategic focus on acute and critical care, anti-aging and preventive medicine development, and international alliances in Asia-Pacific, Europe, and the Americas, while enhancing corporate governance through ESG initiatives and talent strategies as highlighted at the 2025 KPMG Leadership Academy Forum.